David Watson's Insider Trades & SAST Disclosures
David Watson's most recent trade in Apellis Pharmaceuticals Inc was a trade of 82,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Watson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 211.02 per share. | 09 Jun 2025 | 17,969 | 52,132 (0%) | 0% | 211.0 | 3,791,818 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 3,334 | 6,666 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 3,334 | 10,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 230.38 per share. | 09 Jun 2025 | 2,031 | 70,101 (0%) | 0% | 230.4 | 467,902 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.78 per share. | 09 Jun 2025 | 1,553 | 70,189 (0%) | 0% | 36.8 | 57,119 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.47 per share. | 09 Jun 2025 | 1,533 | 71,722 (0%) | 0% | 39.5 | 60,508 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,000 | 5,666 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 09 Jun 2025 | 410 | 72,132 (0%) | 0% | 61.2 | 25,100 | Common Stock |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 9,789 | 9,789 | - | - | Restricted Stock Units | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 6,017 | 102,980 (0%) | 0% | 0 | Common Stock | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 6,017 | 0 | - | - | Restricted Stock Units | |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2025 | 25 | 6,017 | - | - | Restricted Stock Units | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 20,000 | 0 | - | - | Director Stock Option (Right-to-Buy) | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.81 per share. | 14 Mar 2025 | 20,000 | 96,963 (0%) | 0% | 6.8 | 136,200 | Common Stock |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Mar 2025 | 6,667 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Mar 2025 | 6,667 | 0 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 04 Mar 2025 | 5,569 | 138,730 (0%) | 0% | 25.1 | 139,789 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 3,124 | 3,124 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 1,007 | 1,989 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 1,007 | 4,755 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 909 | 881 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 909 | 4,022 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 831 | 0 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 831 | 3,346 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 01 Feb 2025 | 326 | 4,429 (0%) | 0% | 27.6 | 9,001 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 01 Feb 2025 | 274 | 3,748 (0%) | 0% | 27.6 | 7,565 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 01 Feb 2025 | 233 | 3,113 (0%) | 0% | 27.6 | 6,433 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 5,678 | 5,678 | - | - | Restricted Stock Units | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 695 | 144,299 (0%) | 0% | 29.5 | 20,519 | Common Stock |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 3,323 | 144,994 (0%) | 0% | 30.4 | 101,104 | Common Stock |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 42,762 | 148,317 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 2,201 | 105,555 (0%) | 0% | 30.0 | 65,938 | Common Stock |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 4,965 | 107,756 (0%) | 0% | 28.7 | 142,506 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 11,745 | 68,636 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 10,000 | 12,000 | - | - | Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 7,500 | 25,500 | - | - | Earnings Per Share Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 4,000 | 18,001 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 4,000 | 22,001 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 3,334 | 14,667 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 3,333 | 18,001 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 3,000 | 22,000 | - | - | Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 2,286 | 54,933 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 2,000 | 13,334 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 1,958 | 56,891 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 1,856 | 52,647 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 139.89 per share. | 23 Dec 2024 | 500 | 0 (0%) | 0% | 139.9 | 69,945 | Common Stock |
| AMKOR Technology Inc. | N. Watson David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 108 | 5,991 | - | - | Restricted Stock Units | |
| Argan, Inc. | Watson H. David | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 40,000 | 11,334 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | Watson David H. | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.25 per share. | 18 Dec 2024 | 12,502 | 61,291 (0%) | 0% | 64.3 | 803,254 | Common Stock |
| Argan, Inc. | H. Watson David | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 146.05 per share. | 18 Dec 2024 | 10,000 | 51,291 (0%) | 0% | 146.1 | 1,460,500 | Common Stock |
| Argan, Inc. | David Watson H. | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2024 | 500 | 50,791 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 34.24 per share. | 11 Dec 2024 | 5,000 | 112,721 (0%) | 0% | 34.2 | 171,175 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.76 per share. | 05 Dec 2024 | 153 | 2,515 (0%) | 0% | 27.8 | 4,247 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 153 | 4,618 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 153 | 2,668 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 28 | 2,543 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.75 per share. | 05 Dec 2024 | 28 | 2,515 (0%) | 0% | 27.8 | 777 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 28 | 1,790 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 24 | 2,539 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.75 per share. | 05 Dec 2024 | 24 | 2,515 (0%) | 0% | 27.8 | 666 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 24 | 2,996 | - | - | Restricted Stock Units | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Sep 2024 | 10,569 | 117,721 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Sep 2024 | 10,569 | 70,136 (0%) | 0% | 0 | Common Stock | |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2024 | 14 | 5,882 | - | - | Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 58,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 6,666 | 51,334 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.60 per share. | 10 Sep 2024 | 2,241 | 46,589 (0%) | 0% | 54.6 | 122,359 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.78 per share. | 10 Sep 2024 | 2,200 | 48,789 (0%) | 0% | 36.8 | 80,916 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 77.79 per share. | 24 Jul 2024 | 15,134 | 44,348 (0%) | 0% | 77.8 | 1,177,274 | Common Stock |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 12 | 5,867 | - | - | Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 32,000 | 100,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 32,000 | 68,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.60 per share. | 13 Jun 2024 | 9,012 | 53,360 (0%) | 0% | 37.6 | 338,851 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.30 per share. | 13 Jun 2024 | 6,122 | 59,482 (0%) | 0% | 50.3 | 307,937 | Common Stock |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 8,571 | 76,963 (0%) | 0% | 0 | Common Stock | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 8,571 | 0 | - | - | Restricted Stock Units | |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 5,855 | 5,855 | - | - | Restricted Stock Units | |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.87 per share. | 02 May 2024 | 20,000 | 68,392 (0%) | 0% | 9.9 | 197,400 | Common Stock |
| AMKOR Technology Inc. | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2024 | 20,000 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 30,000 | 132,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 10,000 | 28,667 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Apr 2024 | 10,000 | 19,000 | - | - | Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 8,000 | 18,000 | - | - | Earnings Per Share Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.68 per share. | 16 Apr 2024 | 5,367 | 42,419 (0%) | 0% | 41.7 | 223,697 | Common Stock |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 4,000 | 29,000 | - | - | Performance-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Apr 2024 | 4,000 | 24,667 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 3,334 | 18,667 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 3,333 | 21,334 | - | - | Time-Based Restricted Stock Units | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 3,000 | 162,000 | - | - | Option to Purchase Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 2,253 | 37,052 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 1,975 | 34,799 (0%) | 0% | 0 | Common Stock | |
| Argan, Inc. | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2024 | 1,929 | 44,348 (0%) | 0% | 0 | Common Stock | |
| AMKOR Technology Inc. | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 20 | 8,571 | - | - | Restricted Stock Units | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 06 Mar 2024 | 3,762 | 107,152 (0%) | 0% | 13.9 | 52,104 | Common Stock |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 3,762 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 67.77 per share. | 12 Feb 2024 | 781 | 103,390 (0%) | 0% | 67.8 | 52,926 | Common Stock |
| Reynolds Consumer Products... | Clyde David Watson | Chief Legal Counsel/Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 3,020 | 3,020 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | Clyde Watson David | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 909 | 1,818 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products... | David Watson Clyde | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 909 | 2,809 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products... | Watson David Clyde | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 831 | 2,150 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges